Julie Christine Lauffenburger, Ph.D., Pharm.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Medication Adherence | 30 | 2023 | 2055 | 4.630 |
Why?
|
Prescription Drugs | 5 | 2023 | 595 | 1.780 |
Why?
|
Pharmaceutical Services | 6 | 2021 | 140 | 1.600 |
Why?
|
Pharmacy | 2 | 2022 | 91 | 1.470 |
Why?
|
Insurance, Pharmaceutical Services | 4 | 2023 | 336 | 1.350 |
Why?
|
Hypoglycemic Agents | 9 | 2023 | 2866 | 1.350 |
Why?
|
Hypertension | 15 | 2023 | 8455 | 1.340 |
Why?
|
Chronic Disease | 11 | 2021 | 9144 | 1.110 |
Why?
|
Inappropriate Prescribing | 3 | 2021 | 202 | 0.960 |
Why?
|
Diabetes Mellitus, Type 2 | 9 | 2023 | 11695 | 0.940 |
Why?
|
Health Expenditures | 6 | 2023 | 2346 | 0.900 |
Why?
|
Touch Perception | 1 | 2021 | 114 | 0.740 |
Why?
|
Electronic Prescribing | 1 | 2021 | 121 | 0.740 |
Why?
|
Pharmacies | 2 | 2021 | 150 | 0.730 |
Why?
|
Pharmacists | 4 | 2019 | 240 | 0.720 |
Why?
|
Antihypertensive Agents | 7 | 2023 | 2043 | 0.690 |
Why?
|
Reinforcement, Social | 1 | 2018 | 10 | 0.680 |
Why?
|
Gout | 2 | 2023 | 556 | 0.680 |
Why?
|
Cardiovascular Agents | 3 | 2019 | 848 | 0.620 |
Why?
|
Medicare | 11 | 2023 | 6532 | 0.620 |
Why?
|
Nurse Practitioners | 1 | 2021 | 270 | 0.610 |
Why?
|
Glycemic Index | 1 | 2020 | 395 | 0.600 |
Why?
|
Uric Acid | 1 | 2023 | 760 | 0.580 |
Why?
|
Anticoagulants | 4 | 2015 | 4595 | 0.570 |
Why?
|
Metformin | 1 | 2023 | 829 | 0.570 |
Why?
|
Patient-Centered Care | 2 | 2017 | 1436 | 0.560 |
Why?
|
Cardiovascular Diseases | 7 | 2023 | 15108 | 0.560 |
Why?
|
Insulin | 3 | 2020 | 6575 | 0.550 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2023 | 3239 | 0.540 |
Why?
|
Complementary Therapies | 1 | 2020 | 484 | 0.530 |
Why?
|
Warfarin | 2 | 2015 | 1493 | 0.530 |
Why?
|
Medication Therapy Management | 2 | 2017 | 127 | 0.520 |
Why?
|
Medical Informatics | 1 | 2022 | 742 | 0.520 |
Why?
|
Fee-for-Service Plans | 1 | 2020 | 694 | 0.520 |
Why?
|
Community Pharmacy Services | 2 | 2012 | 46 | 0.520 |
Why?
|
Health Care Costs | 2 | 2020 | 3203 | 0.510 |
Why?
|
Vaccines | 1 | 2023 | 817 | 0.500 |
Why?
|
Communication | 4 | 2022 | 3728 | 0.500 |
Why?
|
United States | 29 | 2023 | 69693 | 0.490 |
Why?
|
Cost Control | 1 | 2017 | 624 | 0.490 |
Why?
|
Health Services Needs and Demand | 1 | 2022 | 1411 | 0.470 |
Why?
|
Retrospective Studies | 25 | 2023 | 77098 | 0.470 |
Why?
|
Shock, Septic | 1 | 2020 | 773 | 0.470 |
Why?
|
Medicare Part D | 2 | 2019 | 326 | 0.460 |
Why?
|
Humans | 76 | 2024 | 742088 | 0.450 |
Why?
|
Atrial Fibrillation | 4 | 2015 | 5019 | 0.450 |
Why?
|
Diabetes Complications | 1 | 2020 | 1359 | 0.440 |
Why?
|
Social Support | 1 | 2022 | 2117 | 0.420 |
Why?
|
Polypharmacy | 3 | 2021 | 294 | 0.420 |
Why?
|
Drug Prescriptions | 2 | 2023 | 1636 | 0.410 |
Why?
|
Female | 48 | 2024 | 379592 | 0.410 |
Why?
|
Adrenal Cortex Hormones | 1 | 2020 | 1847 | 0.400 |
Why?
|
Analgesics, Opioid | 3 | 2023 | 3667 | 0.400 |
Why?
|
Diabetes Mellitus | 7 | 2021 | 5724 | 0.400 |
Why?
|
Life Change Events | 1 | 2016 | 937 | 0.390 |
Why?
|
Databases, Factual | 4 | 2016 | 7716 | 0.380 |
Why?
|
Formularies as Topic | 1 | 2011 | 91 | 0.380 |
Why?
|
Middle Aged | 30 | 2023 | 213127 | 0.370 |
Why?
|
Self Report | 4 | 2023 | 3548 | 0.370 |
Why?
|
Male | 40 | 2024 | 349538 | 0.360 |
Why?
|
Aged | 29 | 2024 | 162944 | 0.360 |
Why?
|
Primary Health Care | 5 | 2023 | 4551 | 0.360 |
Why?
|
Pharmacoepidemiology | 1 | 2013 | 323 | 0.360 |
Why?
|
Electronic Health Records | 3 | 2021 | 4440 | 0.360 |
Why?
|
Prescriptions | 2 | 2023 | 387 | 0.350 |
Why?
|
Hyperlipidemias | 4 | 2018 | 786 | 0.350 |
Why?
|
Patient Compliance | 1 | 2019 | 2680 | 0.320 |
Why?
|
Drugs, Generic | 1 | 2013 | 422 | 0.320 |
Why?
|
Patient Participation | 1 | 2017 | 1445 | 0.310 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2015 | 1130 | 0.310 |
Why?
|
Family | 1 | 2018 | 3144 | 0.300 |
Why?
|
Telephone | 2 | 2022 | 617 | 0.300 |
Why?
|
Heart Failure | 4 | 2024 | 10856 | 0.300 |
Why?
|
Sepsis | 1 | 2020 | 2589 | 0.280 |
Why?
|
Telemedicine | 2 | 2021 | 2853 | 0.280 |
Why?
|
Health Behavior | 1 | 2018 | 2630 | 0.280 |
Why?
|
Hepatitis C, Chronic | 1 | 2014 | 1027 | 0.280 |
Why?
|
Decision Making | 2 | 2022 | 3869 | 0.270 |
Why?
|
Drug Costs | 2 | 2023 | 1104 | 0.270 |
Why?
|
Insurance Claim Review | 3 | 2020 | 720 | 0.270 |
Why?
|
Thrombolytic Therapy | 1 | 2015 | 2161 | 0.260 |
Why?
|
Long-Term Care | 2 | 2020 | 607 | 0.260 |
Why?
|
Blood Pressure | 6 | 2023 | 8541 | 0.250 |
Why?
|
Insurance, Health | 1 | 2017 | 2493 | 0.240 |
Why?
|
Physicians | 1 | 2022 | 4554 | 0.240 |
Why?
|
Qualitative Research | 2 | 2022 | 2680 | 0.220 |
Why?
|
Adult | 22 | 2023 | 213712 | 0.220 |
Why?
|
Cholinergic Antagonists | 1 | 2024 | 165 | 0.220 |
Why?
|
Cohort Studies | 9 | 2023 | 40450 | 0.210 |
Why?
|
Atherosclerosis | 3 | 2023 | 3428 | 0.210 |
Why?
|
Antiviral Agents | 1 | 2014 | 2978 | 0.210 |
Why?
|
Internship and Residency | 1 | 2022 | 5774 | 0.200 |
Why?
|
Tranexamic Acid | 1 | 2023 | 146 | 0.200 |
Why?
|
Blood Pressure Determination | 2 | 2022 | 632 | 0.200 |
Why?
|
Gout Suppressants | 1 | 2023 | 160 | 0.200 |
Why?
|
Antifibrinolytic Agents | 1 | 2023 | 254 | 0.190 |
Why?
|
Patient Care | 2 | 2020 | 639 | 0.190 |
Why?
|
Brain Ischemia | 1 | 2015 | 3258 | 0.190 |
Why?
|
Risk Assessment | 4 | 2023 | 23320 | 0.190 |
Why?
|
Blood Glucose | 3 | 2020 | 6249 | 0.180 |
Why?
|
Electronics | 1 | 2021 | 322 | 0.180 |
Why?
|
Administration, Oral | 3 | 2017 | 3913 | 0.180 |
Why?
|
Insurance Carriers | 1 | 2021 | 156 | 0.180 |
Why?
|
Aged, 80 and over | 8 | 2023 | 57683 | 0.170 |
Why?
|
New Jersey | 1 | 2020 | 290 | 0.170 |
Why?
|
Logistic Models | 4 | 2019 | 13403 | 0.170 |
Why?
|
Behavior Control | 1 | 2019 | 45 | 0.170 |
Why?
|
Vaccination | 2 | 2023 | 3256 | 0.170 |
Why?
|
Technology | 1 | 2021 | 303 | 0.160 |
Why?
|
Myocardial Infarction | 3 | 2015 | 11690 | 0.160 |
Why?
|
Postal Service | 1 | 2018 | 96 | 0.160 |
Why?
|
Frail Elderly | 1 | 2023 | 691 | 0.160 |
Why?
|
Drugs, Investigational | 2 | 2018 | 214 | 0.160 |
Why?
|
Medicare Part B | 1 | 2019 | 108 | 0.160 |
Why?
|
Public Health | 1 | 2011 | 2594 | 0.160 |
Why?
|
Remote Consultation | 1 | 2020 | 238 | 0.150 |
Why?
|
Policy | 1 | 2021 | 504 | 0.150 |
Why?
|
Adenosine Diphosphate | 1 | 2018 | 425 | 0.150 |
Why?
|
Risk Factors | 9 | 2023 | 72145 | 0.150 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2022 | 923 | 0.140 |
Why?
|
Reminder Systems | 1 | 2018 | 370 | 0.130 |
Why?
|
Cost Sharing | 1 | 2019 | 407 | 0.130 |
Why?
|
Minority Groups | 1 | 2023 | 1215 | 0.130 |
Why?
|
Cross-Sectional Studies | 3 | 2024 | 24913 | 0.120 |
Why?
|
Biotransformation | 1 | 2014 | 168 | 0.120 |
Why?
|
Comorbidity | 3 | 2020 | 10372 | 0.120 |
Why?
|
Drug Approval | 2 | 2018 | 740 | 0.120 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2021 | 9941 | 0.120 |
Why?
|
Small-Area Analysis | 1 | 2014 | 55 | 0.120 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2014 | 115 | 0.120 |
Why?
|
Follow-Up Studies | 4 | 2020 | 39004 | 0.120 |
Why?
|
Drug Utilization Review | 1 | 2014 | 245 | 0.110 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2016 | 839 | 0.110 |
Why?
|
Prevalence | 3 | 2021 | 15194 | 0.110 |
Why?
|
Education, Pharmacy | 1 | 2012 | 35 | 0.110 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2022 | 1517 | 0.100 |
Why?
|
Referral and Consultation | 2 | 2022 | 3527 | 0.100 |
Why?
|
Patient Care Planning | 1 | 2017 | 921 | 0.100 |
Why?
|
International Normalized Ratio | 1 | 2013 | 365 | 0.100 |
Why?
|
Income | 1 | 2020 | 1904 | 0.100 |
Why?
|
Propensity Score | 2 | 2015 | 1771 | 0.100 |
Why?
|
Odds Ratio | 1 | 2024 | 9846 | 0.100 |
Why?
|
Cross-Over Studies | 1 | 2016 | 2030 | 0.100 |
Why?
|
Adaptation, Psychological | 1 | 2021 | 2575 | 0.100 |
Why?
|
Treatment Failure | 1 | 2016 | 2615 | 0.090 |
Why?
|
Regression Analysis | 2 | 2018 | 6452 | 0.090 |
Why?
|
Malawi | 1 | 2011 | 281 | 0.090 |
Why?
|
Drug Interactions | 1 | 2014 | 1458 | 0.090 |
Why?
|
Health Status Disparities | 1 | 2021 | 1794 | 0.090 |
Why?
|
Research Design | 3 | 2021 | 5979 | 0.090 |
Why?
|
Publishing | 1 | 2016 | 833 | 0.090 |
Why?
|
Socioeconomic Factors | 2 | 2020 | 7770 | 0.080 |
Why?
|
Cesarean Section | 1 | 2017 | 1363 | 0.080 |
Why?
|
Comparative Effectiveness Research | 1 | 2013 | 681 | 0.080 |
Why?
|
Sex Distribution | 1 | 2013 | 2295 | 0.080 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2013 | 1239 | 0.080 |
Why?
|
Public Policy | 1 | 2012 | 572 | 0.080 |
Why?
|
Age Distribution | 1 | 2013 | 2900 | 0.080 |
Why?
|
Survival Analysis | 1 | 2020 | 10248 | 0.080 |
Why?
|
Cost-Benefit Analysis | 1 | 2020 | 5385 | 0.080 |
Why?
|
Drug Utilization | 1 | 2013 | 1181 | 0.070 |
Why?
|
Intensive Care Units | 1 | 2020 | 3679 | 0.070 |
Why?
|
Influenza, Human | 1 | 2018 | 1472 | 0.070 |
Why?
|
Health Personnel | 1 | 2021 | 3210 | 0.070 |
Why?
|
Prognosis | 2 | 2020 | 29010 | 0.070 |
Why?
|
Pain, Postoperative | 1 | 2017 | 1638 | 0.070 |
Why?
|
Focus Groups | 1 | 2012 | 1320 | 0.070 |
Why?
|
Decision Support Techniques | 1 | 2017 | 1952 | 0.070 |
Why?
|
Drug Monitoring | 1 | 2013 | 956 | 0.070 |
Why?
|
Chi-Square Distribution | 1 | 2013 | 3510 | 0.070 |
Why?
|
Young Adult | 4 | 2021 | 56350 | 0.070 |
Why?
|
Drug Therapy, Combination | 1 | 2017 | 6483 | 0.070 |
Why?
|
Bone Density Conservation Agents | 1 | 2013 | 774 | 0.070 |
Why?
|
Intention to Treat Analysis | 2 | 2018 | 425 | 0.070 |
Why?
|
Delivery of Health Care | 2 | 2022 | 5304 | 0.070 |
Why?
|
Reimbursement Mechanisms | 1 | 2012 | 670 | 0.070 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2018 | 3067 | 0.070 |
Why?
|
Treatment Outcome | 3 | 2022 | 62966 | 0.060 |
Why?
|
Sensitivity and Specificity | 1 | 2020 | 14720 | 0.060 |
Why?
|
Evidence-Based Medicine | 2 | 2014 | 3611 | 0.060 |
Why?
|
Adolescent | 4 | 2021 | 85649 | 0.060 |
Why?
|
Opioid-Related Disorders | 1 | 2019 | 2062 | 0.060 |
Why?
|
Combined Modality Therapy | 1 | 2017 | 8621 | 0.060 |
Why?
|
Sex Factors | 2 | 2015 | 10392 | 0.060 |
Why?
|
Residence Characteristics | 1 | 2014 | 2049 | 0.060 |
Why?
|
Osteoporosis | 1 | 2013 | 1581 | 0.060 |
Why?
|
Transcription Factors | 1 | 2024 | 12164 | 0.060 |
Why?
|
Disease Progression | 1 | 2020 | 13256 | 0.060 |
Why?
|
Linear Models | 1 | 2013 | 5948 | 0.050 |
Why?
|
Hemoptysis | 1 | 2023 | 155 | 0.050 |
Why?
|
Digoxin | 1 | 2022 | 250 | 0.050 |
Why?
|
Habits | 1 | 2021 | 137 | 0.050 |
Why?
|
Ambulatory Care | 1 | 2012 | 2706 | 0.050 |
Why?
|
Administration, Inhalation | 1 | 2023 | 1104 | 0.050 |
Why?
|
Longitudinal Studies | 1 | 2017 | 13921 | 0.050 |
Why?
|
Glucagon-Like Peptide 1 | 1 | 2023 | 334 | 0.050 |
Why?
|
Behavioral Sciences | 1 | 2018 | 31 | 0.040 |
Why?
|
Biphenyl Compounds | 1 | 2022 | 914 | 0.040 |
Why?
|
Drug Combinations | 1 | 2022 | 1961 | 0.040 |
Why?
|
Early Termination of Clinical Trials | 1 | 2016 | 68 | 0.040 |
Why?
|
Patient Acceptance of Health Care | 2 | 2022 | 3014 | 0.040 |
Why?
|
Tetrazoles | 1 | 2022 | 835 | 0.040 |
Why?
|
Quality of Health Care | 1 | 2012 | 4369 | 0.030 |
Why?
|
Time Factors | 1 | 2018 | 40054 | 0.030 |
Why?
|
Deductibles and Coinsurance | 1 | 2018 | 316 | 0.030 |
Why?
|
Immunization Programs | 1 | 2018 | 259 | 0.030 |
Why?
|
Antineoplastic Agents | 1 | 2018 | 13655 | 0.030 |
Why?
|
Evidence-Based Practice | 1 | 2018 | 500 | 0.030 |
Why?
|
Hypolipidemic Agents | 1 | 2018 | 604 | 0.030 |
Why?
|
Students, Pharmacy | 1 | 2012 | 17 | 0.030 |
Why?
|
Stroke | 1 | 2015 | 9963 | 0.030 |
Why?
|
Safety | 1 | 2016 | 1185 | 0.030 |
Why?
|
Injections | 1 | 2013 | 840 | 0.020 |
Why?
|
Obstetrics | 1 | 2017 | 657 | 0.020 |
Why?
|
United States Food and Drug Administration | 1 | 2018 | 1581 | 0.020 |
Why?
|
Age Factors | 2 | 2019 | 18355 | 0.020 |
Why?
|
Professional Role | 1 | 2012 | 306 | 0.020 |
Why?
|
Social Class | 1 | 2018 | 1995 | 0.020 |
Why?
|
Stroke Volume | 1 | 2022 | 4983 | 0.020 |
Why?
|
Faculty | 1 | 2012 | 383 | 0.020 |
Why?
|
Neoplasms | 1 | 2018 | 21596 | 0.020 |
Why?
|
Advisory Committees | 1 | 2012 | 773 | 0.020 |
Why?
|
Patient Selection | 1 | 2019 | 4214 | 0.020 |
Why?
|
Medicaid | 1 | 2019 | 2716 | 0.020 |
Why?
|
Risk | 1 | 2018 | 9679 | 0.020 |
Why?
|
Periodicals as Topic | 1 | 2016 | 1431 | 0.020 |
Why?
|
Teaching | 1 | 2012 | 1174 | 0.020 |
Why?
|
Exercise | 1 | 2019 | 5611 | 0.010 |
Why?
|
Prospective Studies | 2 | 2018 | 53187 | 0.010 |
Why?
|
Pregnancy | 1 | 2017 | 29087 | 0.010 |
Why?
|